Veterans Engineering, Training, & Services (VETS, LLC)’s Post

💡 Ever wondered how #AI could play a role in #therapeutics modeling and #drug design? A group of #researchers from Standford has recently developed “SyntheMol”, a generative model (#genAI) that allows for design of new compounds and provides a walk-through method for synthesizing and validating these molecules in laboratory. The group has so far successfully built and validated 6 new #antibiotics able to kill several drug-resistant pathogens. 🦠 Curious to know more? Check this incredible article out! 👉🏻 https://lnkd.in/dd-QeurP #immunity #artificialintelligence #scientificresearch #sciencecommunication #scicomm #network #outreach

Later this month the Newcells Biotech Ltd team are coming to Campus to host a morning of scientific innovation, networking and focused 1-2-1 discussions about predictive models for drug discovery. Book your spot at the seminar on 19 September to find out more about its latest technology advances and their applications including: - Retina: Maximising predictability with functionally validated models - Kidney: Taking control of the future of your compounds through toxicity and efficacy studies for antibody conjugates, antisense oligonucleotides and large molecules - Lung: Achieving more precise assay readouts with high content imaging and functionality validated disease models. Details - https://ow.ly/WVZM50SWznm

More on Insilico's recent paper in Nature Biotechnology which "sets precedent for generative AI in drug discovery" from Sharon Goldman at VentureBeat. ◾ From Insilico's novel AI-discovered target for fibrosis (TNIK) to novel AI-designed drug for idiopathic pulmonary fibrosis currently in Phase II trials, the entire process of discovery and development was accomplished much more quickly and for much less cost than traditional methods. ◾ "With generative AI," she writes, "the company reached the first phase of clinical trials in only two and a half years, at a fraction of the cost." *Link to article in comments. #ai #genai #fibrosis #ipf #drugdiscovery #clinicaltrials #biotech #techbio

Mark Anderson will be presenting on the Biotech Showcase Stage, located in Room 303, on Wednesday, September 11 @ 4:15PM. We invite you to attend and would be happy to schedule time before or after the presentation to meet and discuss Pattern in further detail. Pattern is a pioneer in finding novel patterns in complex data that cannot be discovered using other techniques or tools. The speed of AI innovation is accelerating and is rapidly emerging as a strategic imperative. Pattern is optimally positioned to leverage the expertise of our Pattern Discovery Engine™ (PDE) into the next worlds of trustworthy, transparent computing. Since its founding, Pattern has been on a strategic path with a roadmap largely focused on building our PDE and using it to generate high-value assets, which we are now at an inflection point to commercialize. These assets include and are not limited to: combination cancer drug discoveries and diagnostic advances against the world’s top five cancers, in which we are looking to partner with firms to bring these drugs into clinical trials; the Pattern Discovery Engine™; ProSpectral™, a game-changing medical diagnostic tool and research instrument; and TrueXAI™. These products have already led to major new pattern discoveries in the most competitive and important fields of endeavor. With continued innovation and collaboration, we can create a better future for everyone. LSX - partnering for Life Science eXecutives #biotech #drugdiscovery #advancedcomputing #innovation

Join us at the #BioIT World Conference & Expo! We're excited to be part of the leading event that showcases the latest in precision medicine technology. Find the Ardigen team, including Livia Legg, Agata Miezaniec, PhD, Kamil Malisz and Piotr Faba, at booth 518 where we have a packed agenda of presentations and discussions. We will be presenting two posters: 🔹 P03: "AI Driven Target Discovery and Validation Bridging In Vitro Models and Tumor Characteristics for Personalized Therapy." 🔹 P04: "Integrating Cheminformatics and Phenotypic Screening: A Novel Approach for Enhanced Mode of Action Prediction." At our booth, you can expect short demos: 🔹 A live demo of our Data and Experiment Management Platform. 🔹 A demo of our capabilities in Bioinformatics Workflows. 🔹 Our advancements in AI for Protein Design, Screening, and Optimization. Connect with us! Book a meeting with us at the conference by signing up here: https://lnkd.in/ddGQv4zd #BioITExpo #PrecisionMedicine #Bioinformatics

💉 “We can discover drugs for previously undruggable targets!” 💊 In the last episode of the series, Mati Gill from AION Labs dives into the potential of computational science and AI for drug discovery, and its applications to areas beyond biotechnology! Tune in if you want to understand the breadth of the transformation currently happening through this industry we call TechBio, and what it means for healthcare’s future! 🎙️ Link to the full conversation in the comments: 👇 #TechBio #MedicalAI #Innovation

Looking forward to demonstrating how ENHANC3D GENOMICS and 3D genomics can impact drug development at BioTechX this week. Distal control of gene regulation by enhancers can define new drug targets, refine mechanism of action and support patient stratification. Please reach our to Kishen Chahwala, PhD for a meeting if you'd like to learn more. #BioTechX2024 #Biotechnology #Innovation #Networking

At Itay&Beyond, we're taking drug development for psychiatric and neurological disorders to a whole new level. Instead of relying on outdated animal models, we’re using brain-on-a-chip technology—growing mini-brains from a single patient cell, collected without any invasive procedures. Pretty wild, right? Our organoids actually mimic real human brain activity, and they’re connected to computer interfaces, giving us functional readouts that help predict drug success early on. This isn’t just innovation for the sake of it; with the FDA now accepting organoid data as a substitute for animal testing, it’s real progress. In just a few years, we’ve validated our tech, filed patents, and partnered with some incredible pharma companies. Our mission? To make breakthroughs that lead to real treatments for the millions who need them. Check out our pitch video to see what we’re building at Itay&Beyond, and join us in rethinking what’s possible.